Ingredient or product comparison
Clinical and Research Evidence: Injection vs Topical Application
Controlled studies comparing GHK-Cu delivery routes are limited but directionally consistent. A 2015 study in the Journal of Drugs in Dermatology evaluated topical GHK-Cu cream (1% concentration) applied twice daily for 12 weeks on photoaged skin. Results show
This source-based comparison does not add ratings or recommend a winner.
- Controlled studies comparing GHK-Cu delivery routes are limited but directionally consistent. A 2015 study in the Journal of Drugs in Dermatology evaluated topical GHK-Cu cream (1% concentration) applied twice daily for 12 weeks on photoaged skin. Results showed modest improvement in fine lines and skin texture scores, but histological analysis revealed no significant increase in dermal collagen density. The improvement was attributed primarily to hydration and epidermal thickening. Not collagen remodeling.
- Contrast that with research on injectable copper peptides for wound healing published in Wound Repair and Regeneration. Subcutaneous GHK-Cu injections (5 mg/dose, three times weekly) administered around surgical incision sites accelerated wound closure by 28% compared to saline controls and increased tensile strength of healed tissue by 35% at 21 days post-injury. Immunohistochemistry confirmed elevated collagen type I and III deposition in the injection group. Evidence of active fibroblast stimulation, not just surface-level hydration. These are fundamentally different outcomes.
- The pattern holds for hair regrowth protocols, where GHK-Cu is used to stimulate follicular stem cells. Topical application shows inconsistent results. Some users report increased hair density, others see no change. Injectable GHK-Cu administered via mesotherapy (intradermal microinjections) into the scalp produces more reliable follicle activation. A pilot study in Dermatologic Surgery using monthly scalp injections of GHK-Cu (2 mg per session) reported visible hair density increase in 64% of participants at six months, with dermoscopy confirming increased anagen-phase follicles. Systemic absorption allows the peptide to reach deeper follicular bulbs where stem cell niches reside.
- | Delivery Method | Bioavailability | Tissue Depth Reached | Collagen Synthesis Effect | Molecular Stability | Ease of Use | Professional Assessment ||—|—|—|—|—|—|| Topical Cream | 5–10% dermal absorption | Epidermis and upper dermis only | Minimal. Primarily hydration and surface texture improvement | Poor. Degrades 30–40% within 60 days of opening | High. Apply twice daily at home | Suitable for superficial cosmetic goals only; insufficient for measurable tissue remodeling || Subcutaneous Injection | 40–60% systemic bioavailability | Reaches dermis, subcutaneous tissue, and systemic circulation | Significant. Elevates procollagen markers within 72 hours, increases dermal collagen density | Excellent when stored as lyophilized powder and reconstituted before use | Moderate. Requires injection skill and sterile technique | Gold standard for wound healing, hair regrowth, and systemic anti-inflammatory research protocols || Intramuscular Injection | 50–70% systemic bioavailability | Full